0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Chromogranin A Messenger RNA Expression in the Rat Anterior Pituitary Is Permissively Regulated by the Adrenal Gland

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The influence of the adrenal gland on the expression of chromogranin A in the anterior pituitary was studied in the rat. Adrenalectomy caused a progressive and pronounced (20% of control levels at day 10 after adrenalectomy) decrease of Chromogranin A mRNA levels in anterior pituitary. Daily injection of dexamethasone (15 µg/animal, s.c.) fully reversed the postadrenalectomy decrement in chromogranin A mRNA levels. Chromogranin A protein content, however, was unchanged 10 days after adrenalectomy. In contrast, pro-opiomelanocortin mRNA levels were significantly elevated after adrenalectomy and restored to normal by dexamethasone, with a time course similar to the changes in chromogranin A mRNA levels. These data demonstrate that the adrenal gland permissively regulates chromogranin A expression in the anterior pituitary, at a pretranslational locus, and that this regulation is probably mediated by glucocorticoids.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1989
          1989
          02 April 2008
          : 49
          : 1
          : 107-110
          Affiliations
          aUnit on Molecular and Cellular Neurobiology, Laboratory of Cell Biology, National Institute of Mental Health, Bethesda, Md., USA, and bDepartment of Pharmacology, University of Innsbruck, Austria
          Article
          125098 Neuroendocrinology 1989;49:107–110
          10.1159/000125098
          2716945
          © 1989 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 4
          Categories
          Original Paper

          Comments

          Comment on this article